Why choose our Life Sciences lawyers?
Our go-to team offers clients creative legal and commercial strategies in this highly competitive and complex area. With expertise stretching across regulatory - where we advise the regulators as well as the regulated, intellectual property - particularly involving patents, and data privacy – where we advise across multiple jurisdictions, we are on hand to offer flexible, practical counsel on any client issue.
We are deeply involved in the industry networks and understand the scientific and commercial issues as well as the legal ones. Among our lawyers are PhD scientists and other industry specialists who truly understand the sector, giving clients advice which is comprehensive, rooted in practical know-how and based on decades of experience.
Unlike other law firms, we are also firmly on the pulse in Brussels, staying up to date with the EU's latest political and ethical agendas. This unique insight means we, and our clients by extension, are the first to know and respond to the latest regulatory developments.
We provide a one-stop shop of specialist, integrated legal support in the area of pharmaceuticals, biotechnology, medical devices, healthcare, medicinal cannabis and CBD, agrochemicals and nutraceuticals. We have market-leading experts in France, UK, Germany, Belgium and Spain.
Thanks to our wide geographical reach we have expert insights in the markets where our clients operate, guaranteeing them a bespoke and localised service. We are based in offices around the UK and Europe with an additional network extending into the CIS, Russia, Asia, Australia, and North and South America.
White paper – The future of medicine: Cell and gene therapy
In this paper we look at the cell and gene therapy landscape across key hotspots in Europe, examining the opportunities and challenges for those involved, particularly the regulatory and commercial law issues blocking the pathway from lab to patient. This paper also discusses how national healthcare providers across Europe are opening their eyes and pockets to the substantial cost-savings that CGT can provide and with this shift in approach, we look at what this means for the future of CGT in the UK and across the rest of Europe.
Notable deals and highlights
- Advising Roche Products Limited on its contributions unlicensed medicines for treatment for and help with management of the Covid-19 virus, including various aspects of the clinical trials processes. In addition to this, Our Life Sciences team have also continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges. Our team also advised Roche Products on two research collaboration agreements.
- Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment. Fieldfisher advised UK headquartered MedTech company Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
- We further advised Ultromics on complex contracts in relation to them winning a competition for a phase 3 and phase 4 grant sponsored by the NHS and related bodies to implement AI technology into the NHS and the deals generated a number of press articles:
- Ultromics raises $33M in Series B funding to help
transform cardiac disease treatment - Ultromics
- Ultromics Raises $33M in Series B Funding to Help
Transform Cardiac Disease Treatment (prnewswire.com)
- Fieldfisher advises Ultromics on $33 million Series B
funding | Fieldfisher
- Advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for Covid-19. We advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for covid-19, which completed on 10 February 2022. In addition to this, we also advised Synairgen on a major fundraising primarily intended to enable them to progress with the Phase III clinical trials, enrolling participants across multiple countries, and fund manufacturing and device scale-up activities. The transaction was one of largest public fundraisings in the biotech sector for several years and followed a £14 million fundraising Fieldfisher advised the company on in March 2020.
Key contacts
-
-
London, England
- +44 (0)330 460 6397
- Email Janita
-
-
-
Paris, France
- +33 (0)1 70 37 81 00
- Email Olivier
-
-
-
Manchester, England
- +44 (0)161 200 1773
- Email Sarah
-
-
-
Barcelona, Spain
- +34 934 150 088
- Email Héctor
-
-
-
Munich , Germany
- +49 (0)89 620 306 245
- Email Dr. Cord
-
-
-
Munich , Germany
- +49 (0)89 620 306 221
- Email Dr. Stefanie
-
-
-
Brussels, Belgium
- +32 2 742 70 60
- Email Claudio
-
-
-
Milan, Italy
- +39 02 806731
- Email Diego
-
-
-
Brussels, Belgium
- +32 2 742 70 36
- Email Tim
-
-
-
Paris, France
- +33 (0)1 70 37 81 00
- Email Sébastien
-
